Biora Therapeutics Provides Guidance On Anticipated Milestones During 2024; Says We Begin 2024 In The Clinic With Our Phase 1 Study For BT-600, Which Will Be A Major De-Risking Step In The Development Of Our NaviCap Platform
Portfolio Pulse from Benzinga Newsdesk
Biora Therapeutics, Inc. (NASDAQ:BIOR) provided guidance on anticipated milestones for 2024, including the phase 1 study of BT-600, part of the NaviCap platform, aimed at treating ulcerative colitis (UC). The company expects initial phase 1 data in 2-3 months, with a potential phase 1B study in UC patients and a 56-day GLP tox study planned for the second half of 2024. Biora also highlighted progress with its BioJet platform, with ongoing preclinical data generation and potential expansion of pharma collaborations. The NaviCap platform is designed for targeted delivery of therapeutics to the GI tract, and the BioJet platform is for oral delivery of large molecules.
January 16, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biora Therapeutics is set to begin phase 1 studies for BT-600, a key component of its NaviCap platform, and is making progress with its BioJet platform, including collaborations with AstraZeneca and other pharma companies.
The announcement of upcoming milestones, particularly the phase 1 study for BT-600, is a positive development that could de-risk the NaviCap platform and potentially lead to a new treatment paradigm for GI diseases. The progress with the BioJet platform and collaborations with large pharma companies like AstraZeneca could provide non-dilutive funding and further validate the technology. These factors are likely to be viewed positively by investors and could lead to an increase in BIOR's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100